Phibro Q1 net sales up 40% to $363.9M; raises FY2026 adjusted EBITDA guidance to $230-240M

PHIBRO ANIMAL HEALTH CORP

2026-Q1 EPS reported $0.65 revenue$363,893,000

Net sales $363.9M (+40% YoY); net income $26.5M ($0.65 diluted EPS) vs $7.0M ($0.17) prior year.
Adjusted diluted EPS $0.73 (doubled from $0.35); adjusted EBITDA $61.9M (+$31.2M YoY).
Animal Health sales rose 55% to $283.5M, driven by acquired MFA portfolio (+$80.5M incremental).
FY2026 guidance: Adjusted EBITDA raised to $230-240M (28% growth); net sales reaffirmed $1.43-1.48B.
Company launched Restoris™ dental gel for dogs; annual meeting reelected all director nominees and approved say-on-pay every 3 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.